Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 13:13:a24955542.
doi: 10.1055/a-2495-5542. eCollection 2025.

US multicenter outcomes of endoscopic ultrasound-guided gallbladder drainage with lumen-apposing metal stents for acute cholecystitis

Affiliations

US multicenter outcomes of endoscopic ultrasound-guided gallbladder drainage with lumen-apposing metal stents for acute cholecystitis

Yakira David et al. Endosc Int Open. .

Abstract

Background and study aims: EUS-guided gallbladder drainage (EUS-GBD) using lumen apposing metal stents (LAMS) has excellent technical and short-term clinical success for acute cholecystitis (AC). The goals of this study were to determine the long-term clinical outcomes and adverse events (AEs) of EUS-GBD with LAMS.

Patients and methods: A multicenter, retrospective study was conducted at 18 US tertiary care institutions. Inclusion criteria: any AC patient with attempted EUS-GBD with LAMS and minimum 30-day post-procedure follow-up. Long-term clinical success was defined as absence of recurrent acute cholecystitis (RAC) > 30 days and long-term AE was defined as occurring > 30 days from the index procedure.

Results: A total of 109 patients were included. Technical success was achieved in 108 of 109 (99.1%) and initial clinical success in 106 of 109 (97.2%). Long-term clinical success was achieved in 98 of 109 (89.9%) over a median follow-up of 140 days (range 30-1188). On multivariable analysis (MVA), acalculous cholecystitis (odds ratio [OR] 15.93, 95% confidence interval [CI] 1.22-208.52, P = 0.04) and the occurrence of a LAMS-specific AE (OR 63.60, 95% CI 5.08-799.29, P <0.01) were associated with RAC. AEs occurred in 38 of 109 patients (34.9%) at any time, and in 10 of 109 (9.17%) > 30 days from the index procedure. Most long-term AEs (7 of 109; 6.42%) were LAMS-specific. No technical or clinical factors were associated with occurrence of AEs. LAMS were removed in 24 of 109 patients (22%). There was no difference in RAC or AEs whether LAMS was removed or not.

Conclusions: EUS-GBD with LAMS has a high rate of long-term clinical success and modest AE rates in patients with AC and is a reasonable destination therapy for high-risk surgical candidates.

Keywords: Biliary tract; Endoscopic ultrasonography; Intervention EUS; Performance and complications; Quality and logistical aspects.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Conflicts of Interest and Sources of Funding: There was no financial support for this study. Harry Aslanian: Olympus (consultant), Boston Scientific (consultant). Prabhleen Chahal: Advisory council Medtronic, Boston Scientific (consultant). Rabia DeLatour: Ambu (consultant). David L. Diehl: Boston Scientific (consultant). Christopher J. DiMaio: Boston Scientific (consultant, speaker), Medtronic (consultant, speaker). Tamas A. Gonda: Boston Scientific (Research support). Thomas Kowalski: Boston Scientific (consultant), Medtronic (consultant). Nikhil A. Kumta: Boston Scientific (consultant, speaker), Olympus (consultant), Apollo Endosurgery (consultant, speaker). Dan Mullady: Boston Scientific (consultant), Cook (consultant). John Y. Nasr: Boston Scientific (consultant). Jose Nieto: Boston Scientific (consultant). Alexander Schlachterman: Lumendi (consultant), ConMed (consultant), Olympus (consultant), Medtronic (consultant), FujiFilm (consultant). Andrew Storm: Apollo Endosurgery (consultant and research grants), ERBE (consultant), Boston Scientific (research grants). All other authors: No conflicts of interest

Figures

Fig. 1
Fig. 1
Lumen-apposing metal stent.
Fig. 2
Fig. 2
Choledochoduodenostomy with lumen-apposing metal stent.

References

    1. Ansaloni L, Pisano M, Coccolini F et al.2016 WSES guidelines on acute calculous cholecystitis. World J Emerg Surg. 2016;11:25. doi: 10.1186/s13017-016-0082-5. - DOI - PMC - PubMed
    1. Okamoto K, Suzuki K, Takada T et al.Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25:55–72. doi: 10.1002/jhbp.516. - DOI - PubMed
    1. Endo I, Takada T, Hwang TL et al.Optimal treatment strategy for acute cholecystitis based on predictive factors: Japan-Taiwan multicenter cohort study. J Hepatobiliary Pancreat Sci. 2017;24:346–361. doi: 10.1002/jhbp.456. - DOI - PubMed
    1. Alvino DML, Fong ZV, McCarthy CJ et al.Long-term outcomes following percutaneous cholecystostomy tube placement for treatment of acute calculous cholecystitis. J Gastrointest Surg. 2017;21:761–769. doi: 10.1007/s11605-017-3375-4. - DOI - PubMed
    1. Mori Y, Itoi T, Baron TH et al.Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos) J Hepatobiliary Pancreat Sci. 2018;25:87–95. - PubMed

LinkOut - more resources